Point72 Asset Management L.P. Buys 36,300 Shares of AnaptysBio, Inc. (NASDAQ:ANAB)

Point72 Asset Management L.P. grew its holdings in AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 202.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 54,200 shares of the biotechnology company's stock after purchasing an additional 36,300 shares during the quarter. Point72 Asset Management L.P. owned about 0.18% of AnaptysBio worth $1,816,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Values First Advisors Inc. purchased a new position in AnaptysBio in the third quarter worth approximately $49,000. nVerses Capital LLC increased its holdings in shares of AnaptysBio by 700.0% in the third quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company's stock valued at $54,000 after purchasing an additional 1,400 shares during the period. Headlands Technologies LLC lifted its position in AnaptysBio by 444.8% in the second quarter. Headlands Technologies LLC now owns 3,552 shares of the biotechnology company's stock valued at $89,000 after purchasing an additional 2,900 shares during the period. China Universal Asset Management Co. Ltd. grew its stake in shares of AnaptysBio by 81.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,808 shares of the biotechnology company's stock worth $195,000 after purchasing an additional 2,600 shares during the period. Finally, Intech Investment Management LLC acquired a new stake in shares of AnaptysBio in the 3rd quarter worth approximately $229,000.

Insider Activity

In other news, insider Paul F. Lizzul sold 1,500 shares of AnaptysBio stock in a transaction that occurred on Monday, September 23rd. The shares were sold at an average price of $38.67, for a total transaction of $58,005.00. Following the completion of the sale, the insider now owns 15,398 shares in the company, valued at $595,440.66. The trade was a 8.88 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Dennis Mulroy sold 12,220 shares of the firm's stock in a transaction on Monday, September 16th. The stock was sold at an average price of $39.91, for a total value of $487,700.20. Following the completion of the transaction, the chief financial officer now owns 4,744 shares in the company, valued at $189,333.04. This represents a 72.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 22,440 shares of company stock worth $892,936. Company insiders own 33.70% of the company's stock.

Analyst Ratings Changes

Several analysts have recently commented on the stock. HC Wainwright lowered their price target on shares of AnaptysBio from $55.00 to $52.00 and set a "buy" rating on the stock in a research report on Wednesday, November 6th. JPMorgan Chase & Co. reduced their price objective on AnaptysBio from $75.00 to $66.00 and set an "overweight" rating on the stock in a research note on Tuesday, November 12th. UBS Group boosted their target price on shares of AnaptysBio from $23.00 to $33.00 and gave the stock a "neutral" rating in a research report on Wednesday, October 30th. BTIG Research downgraded AnaptysBio from a "buy" rating to a "neutral" rating in a research note on Monday, December 2nd. Finally, Wedbush reissued an "outperform" rating and set a $42.00 price target on shares of AnaptysBio in a report on Thursday, November 14th. Three investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $54.64.

AnaptysBio Trading Up 1.1 %

ANAB stock traded up $0.25 during mid-day trading on Tuesday, hitting $23.13. The stock had a trading volume of 201,365 shares, compared to its average volume of 361,440. The company has a fifty day moving average of $26.95 and a 200 day moving average of $29.69. AnaptysBio, Inc. has a 1-year low of $15.84 and a 1-year high of $41.31. The stock has a market capitalization of $703.85 million, a price-to-earnings ratio of -3.76 and a beta of -0.11.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last announced its earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) EPS for the quarter, topping the consensus estimate of ($1.72) by $0.58. The firm had revenue of $30.02 million for the quarter, compared to the consensus estimate of $7.92 million. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. As a group, sell-side analysts expect that AnaptysBio, Inc. will post -6.02 earnings per share for the current fiscal year.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.